Congratulations Channing Paller for conducting the largest and most definitive analysis of MUTYH in cancer. Now we need to develop therapeutics that target base excision repair (BER) deficiency. Thanks to Foundation Medicine for sharing their database.

Congrats ZorkoNK for your new paper characterizing NK cell landscape in PCa, and the associated clinical and molecular features. Now it’s time for some NK-directed therapeutics in PCa. Thanks to PCF Science for funding this brilliant young investigator. nature.com/articles/s4139…

Dr. Umang Swami presenting data on behalf of the Caris Life Sciences POA at the ASCO #GU24 on outcomes of prostate cancer based on site of metastases and how sites differ in their molecular underpinnings. Neeraj Agarwal, MD, FASCO Emmanuel Antonarakis Rana McKay

GU24: FOXA1 mutations in PCa may have opposing effects. Some increase AR therapy resistance, some enhance ADT/ARSI response, and some cause lineage plasticity. Congrats to @JustinHwangPhD, and thanks to Caris Life Sciences. meetings.asco.org/2024-asco-geni…

💫🌟🔬 🔝Exciting results from the BRCAAway trial on metastatic castration-resistant prostate cancer! 🌟💫
@MahaHussainMD Neeraj Agarwal, MD, FASCO Emmanuel Antonarakis OncoAlert UroToday.com #GU24 ASCO Alberto Bossi Charlene Mantia

🎯 Key Takeaways
🔵Phase 2, multicenter, randomized.
🔵mCRPC

Very interesting study on prostate tumoral features associated with homozygous adrenal-permissive HSD3B1 inheritance, including AR signaling from Emmanuel Antonarakis Justin Hwang and the Masonic Cancer Center, University of Minnesota group ASCO #GU24 PCF Science Desai Sethi Urology Institute

📊 New insights into mCRPC treatment!
🚀 HOXB13 expression in CTCs reveals crucial prognostic info.
💡 Higher HOXB13 linked to adverse outcomes with abiraterone/enzalutamide.
📉 Understanding AR-dependent markers is key for personalized care! #ProstateCancer #Research

Out today (Jan 2): BAT plus Nivo produces PSA responses of 40%, objective responses of 24%, and is linked to higher PD-1 levels and inflammatory gene sig. Congrats to Mark C. Markowski for leading this IIT, and to Bristol Myers Squibb and Prostate Cancer Foundation for funding it. nature.com/articles/s4146…

Prostate cancers with combined BRCA2 and SPOP mutations have greater homologous repair deficiency and increased sensitivity to PARP inhibitors. This is a clinically actionable patient subset! Congrats to our collaborators from 13 centers.
sciencedirect.com/science/articl…

🧐 Ludimila Cavalcante Emmanuel Antonarakis et al discuss role of SPOP mutations in driving opposing molecular and immune landscapes in prostate and endometrial cancers, suggesting need for tailored therapies ➡️ brnw.ch/21wE4hn

Congrats Minas Economides, MD for this provocative (hypothesis-generating) paper potentially linking germline APC mutations to neuroendocrine prostate cancer. sciencedirect.com/science/articl…

KEYLYNK-010 trial: The combination of olaparib plus pembrolizumab did NOT improve PFS or OS relative to abi/enza in unselected mCRPC patients. ascopubs.org/doi/pdf/10.120…

Congrats Ali Arafa for delivering your first Oral ASCO Abstract. Your impactful study shows that germline mutations clearly influence somatic mutation landscapes in BRCA-associated cancers. ascopubs.org/doi/abs/10.120…

Yes, impressive. But… The OS hazard ratio from PROpel (Abi + Olap) for BRCA1/2 pts was 0.29. Here, OS hazard for BRCA1/2 pts is only 0.61. Why??

Congrats ZorkoNK for the largest NK cell profiling study in cancer to date in collaboration with Caris Life Services. Now it’s time to develop safe/effective NK-directed therapeutics

Congratulations, Dr Zorko

Congratulations Ben. great work!

Congrats Ben Miron evaluating genomic features of IDC-P. Emmanuel Antonarakis

Cathy, thanks for leading (and completing) this impactful trial!

Abstr 5087: First study to evaluate PARP inhibition (without ADT) in biochemically-recurrent prostate cancer. 44% response rate in HRR-mutated pts (100% response in BRCA2 pts). ADT is not needed for PARPi efficacy in PCa! Congrats to Cathy Handy Marshall, MD MPH meetings.asco.org/abstracts-pres…